

SKYEPHARMA PLC  
Form 6-K  
May 01, 2007

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May, 2007

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

**SKYEPHARMA TO PRESENT AT 2007 UBS GLOBAL  
GENERIC & SPECIALTY PHARMACEUTICALS CONFERENCE**

Edgar Filing: SKYEPHARMA PLC - Form 6-K

LONDON, UK, MAY 1, 2007-- SkyePharma PLC (LSE: SKP; NASDAQ: SKYE) today announces that the Company's Chief Executive Officer, Frank Condella, will make a presentation at 2007 UBS Global Generic & Specialty Pharmaceuticals Conference in New York, USA. Mr Condella will deliver his presentation on Tuesday 8 May 2007 at 4.30 p.m. (GMT). Investors may access a live webcast of the presentation at [www.skyepharma.com](http://www.skyepharma.com) under the Investor Relations tab. The presentation will be archived for 3 months.

For further information please contact:

SkyePharma PLC  
+44 207 491 1777  
Frank Condella, Chief Executive Officer  
Ken Cunningham, Chief Operating Officer  
Peter Grant, Finance Director

Financial Dynamics  
+44 207 7831 3113  
David Yates  
Deborah Scott

The Trout Group  
+ 1 617 583 1308  
Seth Lewis

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of known molecules to provide a clinical advantage and life-cycle extension. The Company has ten approved products in the areas of oral, inhalation and topical delivery that are marketed throughout the world by leading pharmaceutical companies. For more information, visit [www.skyepharma.com](http://www.skyepharma.com).

END

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ John Murphy

Name: John Murphy  
Title: Company Secretary

Date: May 01, 2007